£414K
The funding round was backed by Co Angel, The North West Fund for Biomedical, and the Central Manchester Foundation Trust.
Gelexir develops an injectable hydrogel to treat back pain and reduce the need for surgery.
Gelexir is a University of Manchester spinout that has developed an injectable hydrogel designed to relieve back pain and potentially replace invasive spinal surgery.
Philippe Jenny
spine surgeon and veteran ex-medical device corporate executive
Hans von Celsing
Executive director
The funding round was backed by Co Angel, The North West Fund for Biomedical, and the Central Manchester Foundation Trust.